Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Meplazumab by Jiangsu Pacific Meinuoke Bio-Pharmarceutical for Malaria: Likelihood of Approval
Meplazumab is under clinical development by Jiangsu Pacific Meinuoke Bio-Pharmarceutical and currently in Phase II for Malaria. According to GlobalData,...
Meplazumab by Jiangsu Pacific Meinuoke Bio-Pharmarceutical for Coronavirus Disease 2019 (COVID-19) Pneumonia: Likelihood of Approval
Meplazumab is under clinical development by Jiangsu Pacific Meinuoke Bio-Pharmarceutical and currently in Phase III for Coronavirus Disease 2019 (COVID-19)...
Meplazumab by Jiangsu Pacific Meinuoke Bio-Pharmarceutical for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID): Likelihood of Approval
Meplazumab is under clinical development by Jiangsu Pacific Meinuoke Bio-Pharmarceutical and currently in Phase III for Post-Acute Sequelae of COVID...